


PHARMACEUTICAL 2022


AbCellera Biologics Inc. Rank 22 of 475







PHARMACEUTICAL 2022





The relative strengths and weaknesses of AbCellera Biologics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of AbCellera Biologics Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 281% points. The greatest weakness of AbCellera Biologics Inc. is the variable Other Expenses, reducing the Economic Capital Ratio by 39% points.

The company's Economic Capital Ratio, given in the ranking table, is 217%, being 494% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	929,800
Cost of Goods Sold	0
Intangible Assets	196,198
Liabilities, Current	120,676
Liabilities, Non-Current	172,160
Other Assets	80,955
Other Compr. Net Income	280
Other Expenses	132,565
Other Liabilities	0
Other Net Income	14,736
Property and Equipment	111,616
Research and Development	62,062
Revenues	375,203
Selling, General and Administrative Expense	41,848

Output Variable	Value in 1000 USD
Assets	1,318,569
Liabilities	292,836
Expenses	236,475
Stockholders Equity	1,025,733
Net Income	153,464
Comprehensive Net Income	153,604
Economic Capital Ratio	217%